2025-06-13-Jefferies-Ascendis_Pharma（ASND）_截至06_06的每周生长激素处方追踪；Skytrofa与CNP显示出协同效应_8页_974kb
报告摘要
USA Biotechnology: Equity Research Summary
Ascendis Pharma (ASND)
🔍 Highlights
- Recommendation: Buy at $170.92 with a price target of $233 (+36%).
- Clinical Data: TransCon CNP + Skytrofa combo showed +4.23 cm/yr AGV vs. baseline in Phase 2 trial for CNP-naive achondroplasia at Wk26, potentially doubling CNP mono-efficacy.
- Product Performance: Weekly hGH products (Skytrofa, Sogroya, Ngenla) saw significant TRx/NRx increases this quarter (Q2'25) compared to prior quarters.
- Company Description: Ascendis Pharma utilizes TransCon technology for sustained drug release, developed in 2006 (Denmark).
- Valuation: Price target based on DCF model with estimated terminal growth.
展开完整摘要
试读结束，高清完整版pdf/doc/ppt,请点下载
